Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

3-Methylglutaconic aciduria--lessons from 50 genes and 977 patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Oral therapy for riboflavin transporter deficiency - What is the regimen of choice?

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. The Natural History of Hearing Loss in Pendred Syndrome and Non-Syndromic Enlarged Vestibular Aqueduct

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cochlear implantation in a 10-year old boy with Pendred syndrome and extremely enlarged endolymphatic sacs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Adaptive Processes in Hearing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Saskia B Wortmann
  • Leo A J Kluijtmans
  • Richard J Rodenburg
  • Jörn Oliver Sass
  • Jessica Nouws
  • Edwin P van Kaauwen
  • Tjitske Kleefstra
  • Lisbeth Tranebjaerg
  • Maaike C de Vries
  • Pirjo Isohanni
  • Katharina Walter
  • Fowzan S Alkuraya
  • Izelle Smuts
  • Carolus J Reinecke
  • Francois H van der Westhuizen
  • David Thorburn
  • Jan A M Smeitink
  • Eva Morava
  • Ron A Wevers
Vis graf over relationer
Elevated urinary excretion of 3-methylglutaconic acid is considered rare in patients suspected of a metabolic disorder. In 3-methylglutaconyl-CoA hydratase deficiency (mutations in AUH), it derives from leucine degradation. In all other disorders with 3-methylglutaconic aciduria the origin is unknown, yet mitochondrial dysfunction is thought to be the common denominator. We investigate the biochemical, clinical and genetic data of 388 patients referred to our centre under suspicion of a metabolic disorder showing 3-methylglutaconic aciduria in routine metabolic screening. Furthermore, we investigate 591 patients with 50 different, genetically proven, mitochondrial disorders for the presence of 3-methylglutaconic aciduria. Three percent of all urine samples of the patients referred showed 3-methylglutaconic aciduria, often in correlation with disorders not reported earlier in association with 3-methylglutaconic aciduria (e.g. organic acidurias, urea cycle disorders, haematological and neuromuscular disorders). In the patient cohort with genetically proven mitochondrial disorders 11% presented 3-methylglutaconic aciduria. It was more frequently seen in ATPase related disorders, with mitochondrial DNA depletion or deletion, but not in patients with single respiratory chain complex deficiencies. Besides, it was a consistent feature of patients with mutations in TAZ, SERAC1, OPA3, DNAJC19 and TMEM70 accounting for mitochondrial membrane related pathology. 3-methylglutaconic aciduria is found quite frequently in patients suspected of a metabolic disorder, and mitochondrial dysfunction is indeed a common denominator. It is only a discriminative feature of patients with mutations in AUH, TAZ, SERAC1, OPA3, DNAJC19 TMEM70. These conditions should therefore be referred to as inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature.
OriginalsprogEngelsk
TidsskriftJournal of Inherited Metabolic Disease
Vol/bind36
Udgave nummer6
Sider (fra-til)913-21
Antal sider9
ISSN0141-8955
DOI
StatusUdgivet - nov. 2013

ID: 42503444